ENADA is the only brand of NADH currently available that is stabilized and is actually protected by several worldwide patents. Competitors continue to try to bypass these patents and introduce NADH products. However, all these products are non-stabilized forms of NADH. When subjected to independent laboratory analysis and validation, the majority of these products do not contain any NADH. The result of the absence of NADH in these products hurts consumers and leaves the impression that NADH is ineffective. Remember, if an NADH product isn’t stabilized, you’re wasting your money.

ENADA’s business mission is to develop and market safe, reliable, effective products, which will improve the quality of life for all people. CO-E1 (NADH) represents a quantum leap forward in our continued quest to develop the highest quality nutritional supplement products. We recognize the need of proving our products are both safe and effective through sound, quantifiable, scientific principles and clinical research studies…not marketing hype. We have invested millions of dollars in research to achieve Investigative New Drug (IND) status for NADH, enabling us to conduct clinical trials. These clinical studies follow strict Pharmaceutical and Drug testing methodology consisting of double blind crossover, placebo controlled human studies. These studies have been conducted at prestigious medical institutions such as Georgetown University Medical Center.

The company’s proprietary manufacturing, marketing and research are based on several solid patents in the nutraceuticals industry. Eight United States patents protect ENADA, including three formulation patents and five patents based on various methods of treatment. Substantial patents have been established, or are pending, in ten European countries, as well as Israel, China, Japan, Canada, Mexico, Taiwan, and Brazil. Overall, over 30 worldwide patents have been issued, or are pending.